BioCentury | Dec 12, 2011
Emerging Company Profile

Sera Prognostics: Predicting preemies

Sera Prognostics Inc. is developing a molecular test that it thinks will accurately predict more than 90% of women at risk for preterm birth, allowing earlier monitoring and preventive treatment. The company raised $19.3 million...
BioCentury | Apr 23, 2009
Distillery Therapeutics

Indication: Neurology

...status Publication and contact information Neurology Bipolar disorder Inter-alpha trypsin inhibitor heavy chain 1 (ITIH1); Inter-alpha trypsin inhibitor heavy chain 3 (ITIH3)...
...risk for bipolar disorder (p=1.8´10-7). Additional associations were found with SNPs in NEK4, GNL3 and ITIH3...
BioCentury | Aug 23, 2004
Company News

Ciphergen other research news

Researchers published in Cancer Research that a pattern of 3 biomarkers detected stage I/II ovarian cancer with 74% sensitivity at 97% specificity in serum samples from 503 women with ovarian cancer, benign pelvic disease or...
Items per page:
1 - 3 of 3